Literature DB >> 16406874

Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.

Benjamin K Canales1, James K Anderson, Juan Premoli, Joel W Slaton.   

Abstract

PURPOSE: While the evidence is clear that patients with carcinoma in situ or high grade T1 TCC of the bladder are at higher risk for developing UUT tumors, the role of imaging the UUT in patients with Ta tumors remains controversial. We hypothesized that the number and frequency of recurrences in patients with Ta disease would allow us to identify a population who should undergo routine UUT surveillance.
MATERIALS AND METHODS: We reviewed our database of 375 patients who underwent resection of a stage Ta TCC between 1975 and 1995. Median followup was 6 years. Patients were stratified according to the presence of an UUT occurrence, rate and timing of superficial recurrences, and grade of the initial bladder tumor.
RESULTS: Among the 375 patients 50% had no bladder recurrence, 25% had 1 tumor, 15% had 2 tumors, and 10% had 3 or more tumors. Average time between tumors was 17 months. UUT tumor developed in 13 patients (3.4%) at an average of 22 months after their initial bladder tumor. A high risk group consisting of patients who had 2 or more bladder recurrences recurring within 12 months of each other were at 4.5-fold the risk of UUT tumor.
CONCLUSIONS: Stage Ta bladder cancer patients with 2 or more recurrences of bladder tumors with a median of less than 12 months between recurrences are at higher risk for developing an UUT tumor and should be considered for more frequent UUT surveillance.

Entities:  

Mesh:

Year:  2006        PMID: 16406874     DOI: 10.1016/S0022-5347(05)00071-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  A 79-year-old man with urothelial carcinoma of the bladder and upper urinary tract.

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

2.  [Aftercare of non-muscle invasive bladder cancer].

Authors:  G B Schulz; B Schlenker; C G Stief
Journal:  Urologe A       Date:  2019-08       Impact factor: 0.639

Review 3.  [Follow-up of bladder cancer : The right examinations at the right time].

Authors:  P Olbert; P J Goebell; A Hegele
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

4.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008

5.  Monitoring of the upper urinary tract in patients with bladder cancer.

Authors:  Rajinikanth Ayyathurai; Mark S Soloway
Journal:  Indian J Urol       Date:  2011-04

Review 6.  The Current Use of Stem Cells in Bladder Tissue Regeneration and Bioengineering.

Authors:  Yvonne Y Chan; Samantha K Sandlin; Eric A Kurzrock; Stephanie L Osborn
Journal:  Biomedicines       Date:  2017-01-06

7.  Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma.

Authors:  Claudio B Murta; Alberto A Antunes; Marcos F Dall'Oglio; Alcides Mosconi; Kátia R Leite; Miguel Srougi
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.